Sirolimus (marketed as Rapamune)

Audience: Transplantation healthcare professionals
FDA notified healthcare professionals of clinical trial data that suggest increased mortality in stable liver transplant patients after conversion from a calcineurin inhibitor (CNI)-based…



No related posts.